Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors

A 5.2 KB CSV file from figshare details a new class of chemical compounds designed to inhibit the deubiquitylases USP25 and USP28. Author Victor Hernandez-Olmos published the dataset in April 2026, describing compounds synthesized by merging structural features of known inhibitors AZ1 and vismodegib. These compounds demonstrate high potency and selectivity in orthogonal assays, with a suitable negative control identified for cellular validation.

Use Cases

• Training predictive models for inhibitor potency based on structural features described in the study.
• Screening for selective USP25/USP28 inhibitors against other ubiquitin-specific proteases using assay results.
• Identifying negative control compounds for validating cellular assay effects.
• Benchmarking new dual-inhibitor compounds against the reported high-potency examples.

Strengths

• Dataset is small (5.2 KB) and likely focused, facilitating quick inspection.
• Compounds are described as exhibiting high potency across multiple orthogonal assays.
• A suitable negative control has been identified, supporting the validity of cellular assay effects.
• Compounds demonstrate excellent selectivity over other ubiquitin-specific proteases.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare, author Victor Hernandez-Olmos.

Collection Method

Data likely results from a medicinal chemistry study synthesizing and testing compounds.

Time Range

Dataset published in April 2026; study timeframe is not specified.

Freshness

Last updated 2026-04-22 15:08:19; freshness should be verified.

Geography

Spatial coverage is not specified.